Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Qianfoshan Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05068349CT.gov For Patients With Ischemic Stroke, Clinically Study the Effectiveness and Safety of Butylphthalide. | — | Unknown | — | — | — |
NCT00724724CT.gov The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Stroke Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 3-N-BUTYLPHTHALIDE (this asset) | Qianfoshan Hospital | Approved | B · 56 |
| Incobotulinumtoxina | Parc de Salut Mar | P4 | BBB |
| Aggrenox | Boehringer Ingelheim | P4 | BBB |
| Atenolol | Northern California Institute of Research and Education | P4 | BBB |
| Dextromethorphan | University of Florida | P4 | BBB |
| Tenecteplase | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Nerinetide | NoNO Inc. | P3 | BBB |
| Rivaroxaban | China National Center for Cardiovascular Diseases | P4 | BBB |
| Aspirin | China National Center for Cardiovascular Diseases | P4 | BB |
+42 more in the Stroke Disorder cohort
Other indications for 3-N-BUTYLPHTHALIDE
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ischemic Stroke | — | P4 | BBB · 72 |
| Transient Ischemic Attack | — | P4 | BBB · 72 |
| Arterial Occlusion | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 3-N-BUTYLPHTHALIDE in Stroke Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/3-n-butylphthalide-stroke-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →